Kyrgyzstan Foreign Regulatory Actions: Reporting Duties for Withdrawals, Recalls and Suspensions Abroad

1. Key takeaways

When a device is subjected to regulatory action in another country or region (withdrawal, recall, suspension, safety alert, refusal of entry, and so on), the relevant information must be conveyed to the competent authority in Kyrgyzstan and its impact assessed. This obligation can be derived from two directions: first, Article 14 of Law No. 216 places the duty to report changes in device data and information on the manufacturer or its authorized representative; second, Article 15 lists the emergence of new systematic data indicating that risks outweigh benefits as a ground for revocation of the registration certificate. Foreign regulatory actions are among the most direct sources of precisely such information under both provisions.

2. Legal basis

1. Article 14 of Law No. 216: the obligation to report changes in device data and information rests with the manufacturer or its authorized representative.
2. Article 15 of Law No. 216: grounds for suspension and revocation of registration certificates, including the emergence of new systematic data indicating that risks outweigh benefits.
3. Cabinet Resolution No. 513, August 27, 2024, Annex 2: the Procedure for Monitoring the Safety, Quality and Effectiveness of Medical Devices.
4. Article 3 of Law No. 216: statutory definition of an adverse event.

Source note: the specific deadlines, forms and channels for conveying information on foreign regulatory actions were not available this round in official wording suitable for verbatim citation. This article therefore does not state a specific number of days; the original text of Annex 2 to Cabinet Resolution No. 513 and the requirements of the competent authority prevail.

3. Expert insights

Insight one: foreign regulatory actions are the most typical form of systematic data.

A company sells the same product in multiple markets. When the competent authority of one market issues a withdrawal, recall or suspension decision, that decision is in itself high-quality systematic data — it is issued by an independent regulator, based on a complete evidentiary record, and is usually public. If the competent authority in Kyrgyzstan learns of the action through public channels while the company has not reported it proactively, the company’s position under Article 15 is directly weakened.

Insight two: the logical starting point of the reporting duty is a change in information, not the occurrence of an event.

Article 14 speaks of the duty to report changes in device data and information. This wording covers more ground than adverse event reporting: when a product is taken off the market in another country, that is a change in product status information; when a product’s labeling must be revised in another country, that is a change in accompanying information. Companies should therefore build their trigger mechanism around the broad concept of information changes, not around adverse events alone.

Insight three: between global vigilance and local compliance, a fixed transmission channel is needed.

The vigilance systems of multinational companies are usually centered on the global headquarters. We recommend that the internal global vigilance process assign a distribution node to every country where the product is marketed — when a decision is made at the global level, transmission and assessment in each market are triggered automatically. For Kyrgyzstan, that node sits with the authorized representative.

Insight four: before transmitting, first assess product identity.

Is the product targeted by the foreign regulatory action the same model, produced at the same manufacturing site, running the same software version as the product registered in Kyrgyzstan? If not, the applicability of the action must be reassessed; if yes, it must be transmitted without delay. We recommend a product identity comparison table comparing four dimensions: model, specification, manufacturing site and software version (sharing the same structure as the approval comparison table in article 13 of this series).

Insight five: a foreign regulatory action usually triggers follow-on actions.

A recall abroad may set off, in sequence: a recall assessment for the Kyrgyz market, changes to the registration dossier, updates to labels and instructions for use, and even a risk of suspension of the registration certificate. We recommend managing foreign regulatory actions as events rather than as notifications — with a complete process running from receipt through assessment, decision, execution and reporting (see article 45 of this series).

4. Practical recommendations

First, assign a distribution node for each marketed country in the global vigilance process. We recommend specifying, once a decision is made at the global level, within what period information is transmitted to each market, who is responsible, and in what form receipt is confirmed.

Second, build a product identity comparison table. We recommend mapping global products against products registered in Kyrgyzstan across the four dimensions of model, specification, manufacturing site and software version, to allow rapid assessment of the applicability of a foreign action.

Third, manage foreign actions as events rather than notifications. We recommend a standard process: receipt → identity assessment → impact assessment → decision (whether local action is required) → execution → reporting to the competent authority → archiving.

Fourth, have the authorized representative handle transmission and follow-up. We recommend stipulating in agreements that the authorized representative is responsible for conveying information to the competent authority, tracking feedback and archiving, while the manufacturer provides the technical assessment and original documents.

Fifth, once the original text of Annex 2 is obtained, verify the transmission requirements. We recommend asking the authorized representative to request the current requirements from the competent authority and updating internal workflows accordingly (this article does not state a specific number of days).

5. Verification checklist

• □ A distribution node for Kyrgyzstan has been assigned in the global vigilance process, with transmission deadlines, responsible persons and confirmation methods defined;
• □ A product identity comparison table has been built, comparing model, specification, manufacturing site and software version;
• □ A standard process is in place: receipt → identity assessment → impact assessment → decision → execution → reporting → archiving;
• □ Agreements specify that the authorized representative handles transmission and follow-up, and the manufacturer provides the technical assessment and original documents;
• □ The original text of Annex 2 to Cabinet Resolution No. 513 has been obtained to verify the transmission requirements for foreign regulatory actions;
• □ Records of foreign regulatory action handling are included in the standing inspection readiness package.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system conformity support, post-market surveillance and vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations and has built stable local cooperation networks in Bishkek, Almaty, Tashkent and Moscow. Working in Chinese, Russian and English, we deliver actionable solutions for foreign manufacturers on the key issues commonly encountered in CIS markets, including authorized representative arrangements, notarization and legalization chains for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources; figures and timelines that cannot be verified are always marked as practical estimates and are never presented as legal requirements drawn from experience.

GRZAN provides registration and compliance support in this country for manufacturers, importers and authorized representatives. For project inquiries on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Regulatory Registration and Compliance Services for Medical Devices